STAT+: Pharmalittle: We’re reading about a Novo setback, support for Replimune’s melanoma drug, and more
STAT News · LC · trust 34/100
An FDA advisory panel recommended use of an experimental Replimune treatment for advanced melanoma that the agency has rejected twice
Read the original at STAT News →
Open in TruthVane →